Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Bartlomiej M Getta, MBBS, Arnab Ghosh, MD PhD, Catherine C. Coombs, MD, Sean Devlin, PhD, Maria Arcila, MD, Abhinita Mohanty, Ross L. Levine, MD, Martin S. Tallman, MD, Ann A. Jakubowski, MD PhD, Sergio A. Giralt, MD, Alan M Hanash, MD PhD

Blood (2016) 128 (22): 3481.

https://doi.org/10.1182/blood.V128.22.3481.3481

Published: 2016

Journal Articles

Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant

Bartlomiej M Getta, MBBS, Sean Devlin, PhD, Molly A. Maloy, MS, Abhinita Mohanty, Maria Arcila, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Sergio A. Giralt, MD, Mikhail Roshal, MD PhD

Blood (2016) 128 (22): 834.

https://doi.org/10.1182/blood.V128.22.834.834

Published: 2016

Journal Articles

RAS Pathway Mutations Are Associated with Proliferative Features and Frequently Co-Occur with TET2 mutationsin Philadelphia Negative MPN Subtypes

Bartlomiej M Getta, MBBS, Emily C Zabor, Sean Devlin, PhD, Kristina Marie Knapp, Minal Patel, BA, Abhinita Mohanty, Marcel van den Brink, MD PhD, Maria Arcila, MD, Ross L. Levine, MD, Rapaport Franck, Raajit K. Rampal, MD, PhD

Blood (2016) 128 (22): 4269.

https://doi.org/10.1182/blood.V128.22.4269.4269

Published: 2016

Journal Articles

Targeted Sequencing Reveals a Relationship Between Mutational Burden and Clinical Phenotype in MPNs

Bartlomiej Getta, MBBS,, Franck Rapaport, PhD, Sean Devlin, PhD, Chen Zhao, MD, Kristina Marie Knapp, Minal Patel, BA, Abhinita Mohanty, Marcel Van Den Brink, MD PhD, Ross L. Levine, MD, Maria Arcila, MD, Raajit K. Rampal, MD, PhD

Blood (2015) 126 (23): 4061.

https://doi.org/10.1182/blood.V126.23.4061.4061

Published: 2015

Journal Articles

Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway

Catherine C. Coombs, MD, Sean Devlin, PhD, Shweta Dixit, BA, Abhinita Mohanty, Kristina Marie Knapp, Maria Arcila, MD, Virginia M. Klimek, MD, Martin S Tallman, MD, Ross L. Levine, MD, Raajit K. Rampal, MD, PhD, Franck Rapaport, PhD

Blood (2015) 126 (23): 2522.

https://doi.org/10.1182/blood.V126.23.2522.2522

Published: 2015

NARROW

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant

RAS Pathway Mutations Are Associated with Proliferative Features and Frequently Co-Occur with TET2 mutationsin Philadelphia Negative MPN Subtypes

Targeted Sequencing Reveals a Relationship Between Mutational Burden and Clinical Phenotype in MPNs

Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway

Email alerts

ASH Publications

American Society of Hematology

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant

RAS Pathway Mutations Are Associated with Proliferative Features and Frequently Co-Occur with TET2 mutationsin Philadelphia Negative MPN Subtypes

Targeted Sequencing Reveals a Relationship Between Mutational Burden and Clinical Phenotype in MPNs

Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only